The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

Expert Rev Anticancer Ther. 2011 Feb;11(2):139-42. doi: 10.1586/era.10.190.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / secondary*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / pathology*
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Lapatinib
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrroles / therapeutic use*
  • Quinazolines / therapeutic use*
  • Sunitinib

Substances

  • Antineoplastic Agents
  • Indoles
  • Protein Kinase Inhibitors
  • Pyrroles
  • Quinazolines
  • Lapatinib
  • Sunitinib